Related CAS #
190602-72-3 (HCl)
190602-73-4 (free)
Synonym
TA-606, TA 606, TA606, TA-606 free
IUPAC/Chemical Name
(((pentan-3-yloxy)carbonyl)oxy)methyl 3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-5-acetyl-2-propyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-4-carboxylate hydrochloride
InChi Key
GEUFBLVOYZGVMX-UHFFFAOYSA-N
InChi Code
InChI=1S/C33H39N7O6.ClH/c1-5-10-28-34-27-17-18-39(21(4)41)30(32(42)44-20-45-33(43)46-24(6-2)7-3)29(27)40(28)19-22-13-15-23(16-14-22)25-11-8-9-12-26(25)31-35-37-38-36-31;/h8-9,11-16,24,30H,5-7,10,17-20H2,1-4H3,(H,35,36,37,38);1H
SMILES Code
CC(N1C(C(OCOC(OC(CC)CC)=O)=O)C2=C(N=C(CCC)N2CC3=CC=C(C4=C(C5=NN=NN5)C=CC=C4)C=C3)CC1)=O.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
666.18
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother. 2009 Dec;63(10):754-61. doi: 10.1016/j.biopha.2009.02.006. PubMed PMID: 19304450.
2: Kashimura T, Hayashi M, Kodama M, Nakazawa M, Abe S, Yoshida T, Tachikawa H, Hanawa H, Kato K, Watanabe K, Aizawa Y. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J. 2003 Sep;44(5):735-44. PubMed PMID: 14587655.
3: Ishizaka N, Nakao A, Ohishi N, Suzuki M, Aizawa T, Taguchi J, Nagai R, Shimizu T, Ohno M. Increased leukotriene A(4) hydrolase expression in the heart of angiotensin II-induced hypertensive rat. FEBS Lett. 1999 Dec 10;463(1-2):155-9. PubMed PMID: 10601658.
4: Hashimoto Y, Ohashi R, Minami K, Narita H. Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol. 1999 Sep;81(1):63-72. PubMed PMID: 10580372.
5: Hashimoto Y, Yabana H, Narita H. Diverse effects of AT1 receptor antagonists on normal blood pressure and regulatory system. Hypertens Res. 1999 Jul;22(2):121-7. PubMed PMID: 10487328.
6: Uehara Y, Hirawa N, Kawabata Y, Numabe A, Gomi T, Ikeda T, Omata M. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus. Am J Hypertens. 1999 Jan;12(1 Pt 1):21-7. PubMed PMID: 10075380.
7: Hashimoto Y, Ohashi R, Kurosawa Y, Minami K, Kaji H, Hayashida K, Narita H, Murata S. Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. J Cardiovasc Pharmacol. 1998 Apr;31(4):568-75. PubMed PMID: 9554806.
